[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Smyth, E.C., Nilsson, M., Grabsch, H.I., van Grieken, N.C. and Lordick, F. (2020) Gastric Cancer. The Lancet, 396, 635-648. https://doi.org/10.1016/s0140-6736(20)31288-5
|
[3]
|
闫超, 陕飞, 李子禹. 2020年全球胃癌负担分析: 聚焦中国流行现状[J]. 中国肿瘤, 2023, 32(3): 161-170.
|
[4]
|
Siegel, R.L., Giaquinto, A.N. and Jemal, A. (2024) Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12-49. https://doi.org/10.3322/caac.21820
|
[5]
|
Choi, S., Kim, N., Park, J.H., Nam, R.H., Song, C. and Lee, H.S. (2022) Effect of Helicobacter pylori Infection and Its Eradication on the Expression of Tight Junction Proteins in the Gastric Epithelium in Relation to Gastric Carcinogenesis. Helicobacter, 27, e12929. https://doi.org/10.1111/hel.12929
|
[6]
|
Duell, E.J., Travier, N., Lujan-Barroso, L., Clavel-Chapelon, F., Boutron-Ruault, M., Morois, S., et al. (2011) Alcohol Consumption and Gastric Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort. The American Journal of Clinical Nutrition, 94, 1266-1275. https://doi.org/10.3945/ajcn.111.012351
|
[7]
|
Larsson, S.C., Bergkvist, L. and Wolk, A. (2006) Fruit and Vegetable Consumption and Incidence of Gastric Cancer: A Prospective Study. Cancer Epidemiology, Biomarkers & Prevention, 15, 1998-2001. https://doi.org/10.1158/1055-9965.epi-06-0402
|
[8]
|
Shikata, K., Kiyohara, Y., Kubo, M., Yonemoto, K., Ninomiya, T., Shirota, T., et al. (2006) A Prospective Study of Dietary Salt Intake and Gastric Cancer Incidence in a Defined Japanese Population: The Hisayama Study. International Journal of Cancer, 119, 196-201. https://doi.org/10.1002/ijc.21822
|
[9]
|
Smyth, E.C., Capanu, M., Janjigian, Y.Y., Kelsen, D.K., Coit, D., Strong, V.E., et al. (2012) Tobacco Use Is Associated with Increased Recurrence and Death from Gastric Cancer. Annals of Surgical Oncology, 19, 2088-2094. https://doi.org/10.1245/s10434-012-2230-9
|
[10]
|
Hasegawa, H., Shitara, K., Takiguchi, S., Takiguchi, N., Ito, S., Kochi, M., et al. (2022) A Multicenter, Open-Label, Single-Arm Phase I Trial of Neoadjuvant Nivolumab Monotherapy for Resectable Gastric Cancer. Gastric Cancer, 25, 619-628. https://doi.org/10.1007/s10120-022-01286-w
|
[11]
|
张栩晨. PD-1抑制剂联合化疗对比单纯化疗新辅助治疗局部晚期胃癌的疗效和安全性分析[D]: [硕士学位论文]. 青岛: 青岛大学, 2023.
|
[12]
|
Golchin, S., Alimohammadi, R., Rostami Nejad, M. and Jalali, S.A. (2019) Synergistic Antitumor Effect of Anti‐PD-L1 Combined with Oxaliplatin on a Mouse Tumor Model. Journal of Cellular Physiology, 234, 19866-19874. https://doi.org/10.1002/jcp.28585
|
[13]
|
Salas-Benito, D., Pérez-Gracia, J.L., Ponz-Sarvisé, M., Rodriguez-Ruiz, M.E., Martínez-Forero, I., Castañón, E., et al. (2021) Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery, 11, 1353-1367. https://doi.org/10.1158/2159-8290.cd-20-1312
|
[14]
|
Yin, Y., Lin, Y., Yang, M., Lv, J., Liu, J., Wu, K., et al. (2022) Neoadjuvant Tislelizumab and Tegafur/Gimeracil/Octeracil (S-1) plus Oxaliplatin in Patients with Locally Advanced Gastric or Gastroesophageal Junction Cancer: Early Results of a Phase 2, Single-Arm Trial. Frontiers in Oncology, 12, Article ID: 959295. https://doi.org/10.3389/fonc.2022.959295
|
[15]
|
Yuan, S., Nie, R., Jin, Y., Liang, C., Li, Y., Jian, R., et al. (2024) Perioperative Toripalimab and Chemotherapy in Locally Advanced Gastric or Gastro-Esophageal Junction Cancer: A Randomized Phase 2 Trial. Nature Medicine, 30, 552-559. https://doi.org/10.1038/s41591-023-02721-w
|
[16]
|
Tang, X., Li, M., Wu, X., Guo, T., Zhang, L., Tang, L., et al. (2022) Neoadjuvant PD-1 Blockade Plus Chemotherapy Induces a High Pathological Complete Response Rate and Anti-Tumor Immune Subsets in Clinical Stage III Gastric Cancer. OncoImmunology, 11, Article ID: 2135819. https://doi.org/10.1080/2162402x.2022.2135819
|
[17]
|
Wang, X., Huang, J., Huang, H., Liu, Y., Ji, C. and Liu, J. (2023) Safety and Efficacy of Immunotherapy plus Chemotherapy as Neoadjuvant Treatment for Patients with Locally Advanced Gastric Cancer: A Retrospective Cohort Study. Investigational New Drugs, 41, 579-586. https://doi.org/10.1007/s10637-023-01379-y
|
[18]
|
Tang, Z., Wang, Y., Liu, D., Wang, X., Xu, C., Yu, Y., et al. (2022) The Neo-Planet Phase II Trial of Neoadjuvant Camrelizumab plus Concurrent Chemoradiotherapy in Locally Advanced Adenocarcinoma of Stomach or Gastroesophageal Junction. Nature Communications, 13, Article No. 6807. https://doi.org/10.1038/s41467-022-34403-5
|
[19]
|
Wei, J., Lu, X., Liu, Q., Fu, Y., Liu, S., Zhao, Y., et al. (2023) Neoadjuvant Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm Phase 2 Trial. Nature Communications, 14, Article No. 4904. https://doi.org/10.1038/s41467-023-40480-x
|
[20]
|
Li, C., Zheng, Y., Shi, Z., Yang, L., Zhang, B., Wang, Z., et al. (2023) 1512MO Perioperative Camrelizumab (C) Combined with Rivoceranib (R) and Chemotherapy (Chemo) versus Chemo for Locally Advanced Resectable Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma: The First Interim Analysis of a Randomized, Phase III Trial (DRAGON Iv). Annals of Oncology, 34, S852. https://doi.org/10.1016/j.annonc.2023.09.1425
|
[21]
|
Cascone, T., William, W.N., Weissferdt, A., Leung, C.H., Lin, H.Y., Pataer, A., et al. (2021) Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nature Medicine, 27, 504-514. https://doi.org/10.1038/s41591-020-01224-2
|
[22]
|
Shen, P., Qiao, B., Jin, N. and Wang, S. (2022) Neoadjuvant Immunoradiotherapy in Patients with Locally Advanced Oral Cavity Squamous Cell Carcinoma: A Retrospective Study. Investigational New Drugs, 40, 1282-1289. https://doi.org/10.1007/s10637-022-01293-9
|
[23]
|
杨盈赤, 庞凯, 张忠涛. 新辅助放疗联合免疫治疗对直肠癌微创术式应用的影响[J]. 外科理论与实践, 2023, 28(3): 186-189.
|